References
- World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015. Cited 2021 Nov 1. http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565_eng.pdf?ua=1
- Marcus JL, Chao CR, Leyden WA, et al. Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals with Cited to Care. J Acquir Immune Defic Syndr. 2016;73(1):39–46. [Cited 2021 Nov 1] https://insights.ovid.com/jaids-acquired-immune-deficiency-syndromes/jaids/2016/09/010/narrowing-gap-life-expectancy-hiv-infected/6/00126334
- Autenrieth CS, Beck EJ, Mallouris C, et al. Global and regional trends of people living with HIV aged 50 and over: estimates and projections for 2000–2020. PLOSONE. 2018;13(11):e0207005. Cited 2021 Nov 1 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0207005.
- Althoff KN, Smit M, Reiss P, et al. HIV and ageing: improving quantity and quality of life. Curr Opin HIV AIDS. 2016;11:527–536. Cited 2021 Nov 1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084838/
- Shah ASV, Stelzle D, Lee KK, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis. Circulation. 2018;138:1100–1112. Cited 2021 Nov 1 https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.117.033369
- Beck EJ, Shields JM, Tanna G, et al. Developing and implementing national health identifiers in resource limited countries: why, what, who, when and how? Glob Health Action. 2018;11(1):1440782. [Cited 2021 Nov 1] https://www.tandfonline.com/doi/full/10.1080/16549716.2018.1440782
- Hyle EP, Naidoo K, Su AE, et al. HIV, tuberculosis, and non-communicable diseases: what is known about the costs, effects, and cost-effectiveness of integrated care? J Acquir Immune Defic Syndr. 2014;67(1):S87–S95. [Cited 2021 Nov 1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147396/pdf/nihms604877.pdf
- Taylor D, Lunny C, Loli P, et al. Effectiveness of text messaging interventions on prevention, detection, treatment, and knowledge outcomes for sexually transmitted infections (STIs)/HIV: a systematic review and meta-analysis. Syst Rev. 2019 Cited 2021 Nov 1;8:12.
- Cooper V, Clatworthy J, Whetham J; the EmERGE Consortium. mHealth interventions to support self-management in HIV: a Systematic Review. Open AIDS J. 2017;11:119–132. Cited 2021 Nov 1. https://openaidsjournal.com/VOLUME/11/PAGE/119/
- Medi-Sfeer. Nieuws – eHealth. https://www.medi-sfeer.be/nl/nieuws/e-health.html Cited 2021 Nov 1
- IAM Newswire. TeleMedicine – one of the first COVID-19 by-products, May 19, 2020. Cited 2021 Nov 1 https://iamnewswire.com/2020/05/19/telemedicine-one-of-the-first-covid-19-by-products/?mod=article_inline
- Cheney C. How to use telehealth in cancer care during the coronavirus pandemic and beyond. HealthLeaders; May 19, 2020. Cited 2021 Nov 1 https://www.healthleadersmedia.com/clinical-care/how-use-telehealth-cancer-care-during-coronavirus-pandemic-and-beyond
- Catalani C, Philbrick W, Fraser H, et al. mHealth for HIV treatment & prevention: a systematic review of the literature. Open AIDS J. 2013;7:17–41. Cited 2021 Nov 1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795408/pdf/TOAIDJ-7-17.pdf
- de La Torre-dı´ez I, Lo´pez-coronado M, Vaca C, et al. Cost-utility and cost-effectiveness studies of telemedicine, electronic, and mobile health systems in the literature: a systematic review. Telemed E-Health. 2015;21(2):81–85.
- Sarabi RE, Sadoughi F, Orak RJ, et al. The effectiveness of mobile phone text messaging in improving medication adherence for patients with chronic diseases: a systematic review. Iran Red Crescent Med J. 2016 May;18(5):e25183. Cited 2021 Nov 1 https://www.researchgate.net/publication/301704083_The_Effectiveness_of_Mobile_Phone_Text_Messaging_in_Improving_Medication_Adherence_for_Patients_with_Chronic_Diseases_A_Systematic_Review
- Kaplan WA. Can the ubiquitous power of mobile phones be used to improve health outcomes in developing countries? Global Health. 2006 Cited 2021 Nov 1;2:9.
- Govindasamy D, Meghij J, Negussi EK, et al. Interventions to improve or facilitate linkage to or retention in pre-ART (HIV) care and initiation of ART in low- and middle-income settings - a systematic review. Journal of the International AIDS Society. 2014 August;17(1):19032. Cited 2021 Nov 1.
- Thirumurthy H, Lester RT. M-health for health behaviour change in resource-limited settings: applications to HIV care and beyond. Bull World Health Organ. 2012;90(5):390–392. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341690/pdf/BLT.11.099317.pdf
- Iribarren SJ, Cato K, Falzon L, et al. What is the economic evidence for mHealth? A systematic review of economic evaluations of mHealth solutions. PLoS ONE. 2017;12(2):e0170581.
- Rout SK, Gabhale YR, Dutta A, et al. Can telemedicine initiative be an effective intervention strategy for improving treatment compliance for pediatric HIV patients: evidences on costs and improvement in treatment compliance from Maharashtra, India. PLoS ONE. 2019 [Cited 2021 Nov 1];14(10):e0223303. https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0223303
- Demena BA, Artavia-Mora L, Ouedraogo D, et al. A systematic review of mobile phone interventions (SMS/IVR/Calls) to improve adherence and retention to antiretroviral treatment in low-and middle-income countries. AIDS Patient Care STDS. 2020;34(2):59–71.
- Chausa P, Gárate FJ, Cáceres C, et al.; the EmERGE Consortium. EmERGE platform: a new mhealth solution for people living with HIV. In: Henriques J, Neves N, de Carvalho P. (editors) XV mediterranean conference on medical and biological engineering and computing – MEDICON 2019. MEDICON 2019. IFMBE proceedings. Vol. 76. Cham: Springer. Cited 2021 Nov 1 https://link.springer.com/chapter/10.1007%2F978-3-030-31635-8_99
- Beck EJ, Gill W, De Lay PR. Protecting the confidentiality and security of personal health information in low- and middle-income countries in the era of SDGs and Big Data. Glob Health Action. 2016;9(1):32089.
- Whitten PS, Mair FS, Haycox A, et al. Systematic review of cost effectiveness studies of telemedicine interventions. BMJ. 2002;324:1434–1437. Cited 2021 Nov 1. https://www.bmj.com/content/324/7351/1434
- Hailey D. The need for cost-effectiveness studies in telemedicine. J Telemed Telecare. 2005 Dec 1;11(8):379–383.
- de Jongh T, Gurol-Urganci I, Vodopivec-Jamsek V, et al. Mobile phone messaging for facilitating selfmanagement of long-term illnesses. Cochrane Database Syst Rev. 2012;12:CD007459. Cited 2021 Nov 1 https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007459.pub2/abstract
- Waldrop G, Doherty M, Vitoria M, et al. Stable patients and patients with advanced disease: consensus definitions to support sustained scale up of antiretroviral therapy. Trop Med Int Health. 2016;21(9):1124–1130.
- UNAIDS. Manual for costing HIV facilities and services. Geneva Switzerland, 23 May 2011. Cited 2021 Nov 1 http://www.unaids.org/en/media/unaids/contentassets/documents/document/2011/20110523_manual_costing_HIV_facilities_en.pdf
- UNAIDS. Workbook for the collection of cost information on HIV facilities and services. Geneva Switzerland, 23 May 2011. Cited 2021 Nov 1 http://www.unaids.org/en/media/unaids/contentassets/documents/document/2011/20110523_workbook_cost_info_en.pdf
- Beck EJ, Yfantopoulos P, Mandalia S. EU deliverable 3.3 costs and unit Costs for EmERGE clinical sites, 20 Mar 2020. EU Grant Agreement No: 643736 For copy of EU Report please contact Corresponding Author.
- Beck EJ, Mandalia S, Yfantopoulos P. EU deliverable 3.4 cost-efficiency of the mHealth pathway at the five EmERGE sites. 29 Apr 2020. EU Grant Agreement No: 643736. For copy of EU Report please contact Corresponding Author.
- West BT, Welch KB, Galecki AT. Linear mixed models. A practical guide using statistical software. Boca Raton Fl: Chapman & Hall/CRC; 2007.
- Beck EJ, Mandalia S, Gaudreault M, et al. The Cost-effectiveness of HAART, Canada 1991-2001. AIDS. 2004;18:2411–2419. Cited 2021 Nov 1 https://journals.lww.com/aidsonline/pages/articleviewer.aspx?year=2004&issue=12030&article=00008&type=Fulltext
- Badri M, Maartens G, Mandalia S, et al. Cost-effectiveness of Highly active antiretroviral therapy in South Africa PLoS Med January 2006;3: e4. Cited 2021 Nov 1 http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.0030004
- Mandalia S, Mandalia R, Lo G, et al. Rising population cost for treating people living with HIV in the UK, 1997-2013. PLoS ONE. 2010;5(12):e15677. [Cited 2021 Nov 1] http://www.plosone.org/article/info:doi/10.1371/journal.pone.0015677
- SAS Institue , Inc SAS/ACCESS9.4 Interphase to ADABAS Reference. Cary NC: SAS Institute Inc; 2014.
- Hibbard JH, Mahoney ER, Stockard J, et al. Development and testing of a short form of the patient activation measure. Health Serv Res. 2005;40(6p1):1918–1930.
- Duracinsky M, Herrmann SE, Berzins B, et al. The development of PROQOL-HIV: an International Instrument to assess the health-related quality of life of persons living with HIV/AIDS. J Acquir Immune Defic Syndr 2012;59:498–505. Cited 2021 Nov 1. https://www.researchgate.net/publication/51977525_The_development_of_PROQOL-HIV_An_international_instrument_to_assess_the_health-related_quality_of_life_of_persons_living_with_HIVAIDS
- Wikipedia. Incremental cost-effectiveness ratio. Cited 2021 Nov 1 https://en.wikipedia.org/wiki/Incremental_cost-effectiveness_ratio
- Beck EJ, Mandalia S, Yfantopoulos P, et al. Ensuring continuity of care for people living with HIV in Five European Countries: the efficiency of the EmERGE Platform. HIV Drug Therapy Glasgow 2020 Poster. Cited 2021 Nov 1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533869/
- Beck EJ, Mandalia S, Yfantopoulos P, et al. Efficiency of the EmERGE pathway to provide continuity of care for Spanish people living with medically stable HIV. Enferm Infecc Microbiol Clin. 2020; Cited 2021 Nov 1. accepted. DOI:10.1016/j.eimc.2020.11.018.
- Beck EJ, Mandalia S, Yfantopoulos P, et al. The cost of care for people living with stable HIV in Croatia and the efficiency of EmERGE. Croation Med J. In Press;
- Jones CI, Bremner S, Whetham J. EU D6.2 Report on clinical outcomes; patient empowerment and quality of life analyses; patient experience & usability. https://cordis.europa.eu/project/id/643736/results. Filed under: “Documents/Reports/ Report on PROMs and PREMs, patient empowerment and Quality of Life analysis”. (Cited 1-11-2021)
- Beck EJ, Mandalia S, DongmoNguimfack B, et al. Does the political will exist to bring quality-assured and affordable drugs to low- and middle-income countries? Glob Health Action. 2019;12(1):1586317.
- Beck EJ, Mandalia S, Sangha R, et al. Lower healthcare costs associated with the use of a single-Pill ARV regimen in the UK, 2004-2008. PLoSONE. 2012;7(10):e47376. [Cited 2021 Nov 1] http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0047376
- Ward D, Ramgopal M, and Riedel DJ, et al. Real-world experience with dolutegravir-based two-drug regimens, AIDS Research and Treatment . 2020;8:5923256.
- Despiegel N, Anger D, Martin M, et al. Cost-effectiveness of dolutegravir in HIV-1 treatment-naive and treatment-experienced patients in Canada. Infect Dis Ther. 2015;4:337–353. Cited 2021 Nov 1.
- Davis W, Mantsios A, Karver T, et al. “It made me more confident that I have it under control”: patient and provider perspectives on moving to a two-drug ART regimen in the United States and Spain. PLoS ONE. 2020;15(5):e0232473.
- Decock RC, Depoorter A-ME, De Graeve D, et al. Direct costs of health care for HIV/AIDS patients in Belgium. AIDS Care;2010:721–731. Cited 2021 Nov 1 https://www.tandfonline.com/doi/abs/10.1080/09540120120076887
- Rémy Demeester R. HIV/AIDS cost-effectiveness: clinical/in practice. 5th BREACH Symposium 25 Nov 2016, Charleroi, Belgium. Cited 2021 Nov 1 http://breach-hiv.be/wp-content/uploads/2018/11/2-cost-effectiveness-clinical-in-practice-Demeester.pdf
- Marent B, Henwood F; the EmERGE Consortium. Platform encounters: a study of digitised patient follow-up in HIV care. Sociol Health Illn. 2021;1–19. Cited 2021 Nov 1 https://onlinelibrary.wiley.com/doi/10.1111/1467-9566.13274
- Wright JH, Caudill R. Remote treatment delivery in response to the COVID-19 pandemic. Psychother Psychosom. 2020;89:130–132. Cited 2021 Nov 1. https://www.karger.com/Article/Pdf/507376
- Hall JL, McGraw D. For telehealth to succeed, privacy and security risks must be identified and addressed. Health Affairs. 2014;33(2):216–221.
- UNAIDS. The privacy, confidentiality and security assessment tool: protecting personal health information. Geneva. 14 Feb 2019. Cited 2021 Nov 1 http://www.unaids.org/en/resources/documents/2019/confidentiality_security_assessment_tool
- mHealthBELGIUM: the Belgian platform for mobile applications that are CE-marked as a medical device. Cited 2021 Nov 1 https://mhealthbelgium.be/
- WHO/International Bank for Reconstruction and Development/The World Bank. Tracking universal health coverage: 2017 global monitoring report; 2017. Cited 2021 Nov 1 https://apps.who.int/iris/bitstream/handle/10665/260522/WHO-HIS-HGF-17.2-eng.pdf;sequence=1